AstraZeneca PLC/ US0463531089 /
2024-07-31 10:00:00 PM | Chg. +1.2500 | Volume | Bid11:31:37 AM | Ask11:31:37 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
79.1500USD | +1.60% | 5.55 mill. Turnover: 272.06 mill. |
78.4300Bid Size: 400 | 78.4600Ask Size: 1,100 | 244.73 bill.USD | - | 20.61 |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
---|
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Company data
Name: | AstraZeneca plc |
Address: | 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
Phone: | 0800 783 0033 |
Fax: | +44-20-7604-8151 |
E-mail: | Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com |
Internet: | www.astrazeneca.com |
Industry: | Healthcare |
Sector: | Pharmaceutical Industry |
Sub sector: | Pharmaceuticals |
End of financial year: | 12-31 |
Free Float: | - |
IPO date: | 1999-04-06 |
Investor relations
Name: | Andy Barnett |
IR phone: | +44 (0)20 3749 5000 |
IR Fax: | - |
IR e-mail: | CorporateAccess@astrazeneca |